about
Isolation, purification and preliminary X-ray characterization of Cpn60-2 (65 kDa heat-shock protein) from Mycobacterium tuberculosisDirect visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporationRecognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.TLR4 Expression Is Associated with Left Ventricular Dysfunction in Patients Undergoing Coronary Artery Bypass SurgeryIsolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansionIn-vitro Optimization of Nanoparticle-Cell Labeling Protocols for In-vivo Cell Tracking ApplicationsEnhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.T-cell receptor gene therapy of established tumors in a murine melanoma modelStable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognitionGenetically modulating T-cell function to target cancer.Out of the bitter came forth sweet: Activating CD28-dependent co-stimulation via PD-1 ligands.A novel lncRNA, GASL1, inhibits cell proliferation and restricts E2F1 activity.Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T-Cells in Vivo with Gold Nanoparticles and CT Imaging.Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity.MHC-multimer guided isolation of neoepitopes specific T cells as a potent-personalized cancer treatment strategy.Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming.Simple sequence repeats in Escherichia coli: abundance, distribution, composition, and polymorphismExtended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells.Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.Simultaneous monitoring of binding to and activation of tumor-specific T lymphocytes by peptide-MHC.Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy.Engineering T-Cell Specificity Genetically to Generate Anti-melanoma Reactivity.The mutational status of p53 can influence its recognition by human T-cells.Increased RNA Editing May Provide a Source for Autoantigens in Systemic Lupus Erythematosus.Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificityIsolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytiGeneration of recombinant immunotoxins for specific targeting of tumor-related peptides presented by MHC moleculesCXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapyA TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor functionT-cells "à la CAR-T(e)" - Genetically engineering T-cell response against cancerTargeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells
P50
Q28487297-B60F86BC-D63D-4DD0-87A6-E306D15B5BB7Q34035564-FD22158E-2079-4859-B71F-8D8D578293F9Q34657652-FD8BC7C9-F46F-486E-B418-DB5FF49E3CA1Q34657661-0A6623EF-35A5-42C2-8A26-CF12BE446A24Q34786615-35DC81F5-2430-42E7-8571-2467AA4320BBQ35648432-7753E0A9-BAA4-4A25-9E31-F56D2A2774E8Q36165605-2D86E65D-B669-485F-AEE6-915FBB50EE46Q36215613-BD3C3EF2-7116-4537-BF01-506A6566D959Q36216873-BD51D703-5E0F-4B08-83A0-46BC7A0BCD8AQ36286122-E04C3726-F052-4322-ACE1-750A46F323F6Q36311669-C993E3AE-BE0F-4A9A-98D7-8450CE29822EQ36449599-B36CA65B-D2FA-4EDB-B15D-2458604414A7Q37043492-6E8FC86D-BACB-464D-AEE5-8BB619BA41DFQ37197942-BEDE1A0D-11E9-4E47-92E4-553CF42A4234Q37972528-3B124000-5C8D-40C1-AACD-9793583B7CFEQ38627207-CAB2D110-2E95-4983-9A7E-F8DA22402547Q38830087-7BC2D984-FDEE-408E-A8EB-072A764DCC4DQ38867979-6206E61A-73B3-48AB-BB48-10F4522602CCQ39097038-8F1681F7-1A88-4192-8399-1A8BB277F60EQ39356556-49EE56B2-0DC9-4F15-8C44-48863424E369Q39397403-48D0B1E5-A83B-47DD-9C0F-4B7A1A8F22DEQ40221124-68D2264B-F429-4EF5-936B-DC8412C08CB7Q40412255-588B6561-5FEA-44BE-A869-6524A403FDA5Q40551878-6DEDB69E-5BAA-4032-B45D-78F579F599E9Q41958978-463762FD-CDF1-4259-A49C-995204234535Q44473369-23AB8454-4776-4FB5-8C7C-3EB12D86BC1BQ47111488-6DFD0D7B-BD52-4E01-AEE1-D201E0F828A0Q47447851-8DB7BC6C-9E38-40B2-B8F7-226C57606CF5Q50043619-49A41155-AFB4-4839-90FF-1E20D99D9E3EQ50999703-503B2495-8ED6-4167-BF7E-C3491E961D11Q52607307-78A21C95-643E-4404-8A5B-8A0E44E587C2Q53943139-17F3DC42-8780-4EAF-B5E6-366D8314F5CDQ58380161-656DCF12-DAFA-43B1-BB99-EA0EAD1520A2Q78464154-544C6343-1930-4B80-9DED-19B8AFEA8A04Q83731741-B860E991-010E-4A17-8F6C-D2730A5C9306Q89998371-AF9280E4-0062-4100-AE5B-6C3925E13C00Q91091375-4EBD1D40-0A2A-4223-B2AB-CB8F6BD0EF2CQ94551231-4E2A9AD0-984F-49A9-93F0-3AA8F66E11A8
P50
description
researcher
@en
name
C J Cohen
@en
C J Cohen
@nl
type
label
C J Cohen
@en
C J Cohen
@nl
prefLabel
C J Cohen
@en
C J Cohen
@nl
P106
P31
P496
0000-0002-0619-5959